NCT00705484View on ClinicalTrials.gov

European Safety Registry in Ulcerative Colitis (P04808)

CompletedOBSERVATIONAL
Enrollment

2,239

Participants

Timeline

Start Date

June 1, 2007

Primary Completion Date

October 20, 2016

Study Completion Date

October 20, 2016

Conditions
Ulcerative Colitis
Interventions
BIOLOGICAL

infliximab

The treating physician will determine the treatment regimen and dose of Remicade.

DRUG

Standard Therapy

The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00705484 - European Safety Registry in Ulcerative Colitis (P04808) | Biotech Hunter | Biotech Hunter